Adapting Traditional Drug Development Methods for Epigenetic Therapies- Peter Staller
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field.
TO READ THE FULL STORY
Please note: That all fields marked with an asterisk (*) are required.